GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE106291 Query DataSets for GSE106291
Status Public on Dec 16, 2017
Title A 29-Gene and Cytogenetic Score for the Prediction of Resistance to Induction Treatment in Acute Myeloid Leukemia
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Primary therapy resistance is a major problem in acute myeloid leukemia treatment. We set out to develop a powerful and robust predictor for therapy resistance for intensively treated adult patients. We used two large gene expression data sets (n=856) to develop a predictor of therapy resistance, which was validated in an independent cohort analyzed by RNA sequencing (n=250). In addition to gene expression markers, standard clinical and laboratory variables as well as the mutation status of 68 genes were considered during construction of the model. The final predictor (PS29MRC) consisted of 29 gene expression markers and a cytogenetic risk classification. A continuous predictor is calculated as a weighted linear sum of the individual variables. Additionally, a cut off was defined to divide patients into a high-risk and a low-risk group for resistant disease. PS29MRC was highly significant in the validation set, both as a continuous score (OR=2.39; p=8.63·10-9, AUC=0.76) and as a dichotomous classifier (OR=8.03; p=4.29·10-9). The accuracy was 77%. In multivariable models, only TP53 mutation, age and PS29MRC (continuous: OR=1.75; p=0.0011; dichotomous: OR=4.44, p=0.00021) were left as significant variables. PS29MRC dominated all models when compared with currently used predictors and also predicted overall survival independently of established markers. When integrated in the European LeukemiaNet 2017 genetic risk stratification, four groups (median survival [months] of 8, 18, 41, not reached) could be defined (p=4.01·10-10). PS29MRC will make it possible to design trials which stratify induction treatment according to the probability of response and refines the ELN 2017 classification.
Overall design The set consists of all patients with available material treated in the AMLCG-2008 study (NCT01382147, n=210) and additional 40 patients with resistant disease that were treated in the AMLG-1999 trial (NCT00266136). RNAseq libraries were prepared using the Sense mRNA Seq Library Prep Kit V2 (Lexogen, n=238) and the TruSeq RNA Library Preparation V2 Kit (Illumina, n=12). Between 500-1000 ng total RNA (RNA integrity number [RIN] >7) were used as input material. All sequencing was paired end and performed using polyadenylated-selected and, in case of the Lexogen libraries, stranded RNA sequencing. Samples were sequenced on a HiSeq 1500 instrument (Illumina) as 100 bp reads to a targeted depth of 20 million mappable paired reads per sample.
Contributor(s) Herold T, Jurinovic V, Batcha AM, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, Hartmann L, Greif PA, Phillippou-Massier J, Krebs S, Blum H, Amler S, Sauerland MC, Görlich D, Berdel WE, Woermann BJ, Braess J, Hiddemann W, Metzeler KH, Mansmann U, Spiekermann K
Citation(s) 29242298
Submission date Oct 27, 2017
Last update date Oct 02, 2018
Contact name Tobias Herold
Organization name University Hospital Grosshadern, Ludwig-Maximilians-University (LMU)
Department Department of Internal Medicine III
Street address Marchioninistr. 15
City Munich
ZIP/Postal code 81377
Country Germany
Platforms (1)
GPL18460 Illumina HiSeq 1500 (Homo sapiens)
Samples (250)
GSM2835244 GEO-13
GSM2835245 GEO-14
GSM2835246 GEO-15
BioProject PRJNA416133

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE106291_Matrix_table.xlsx 58.4 Mb (ftp)(http) XLSX
GSE106291_RAW.tar 21.8 Mb (http)(custom) TAR (of TXT)
Raw data not provided for this record
Processed data provided as supplementary file
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap